Kovaltry Market Report 2026

Kovaltry Market Overview

• The Kovaltry market growth in the historic period has been driven by safety concerns with plasma derived factors, improved recombinant technology • Market expansion is supported by increasing adoption of prophylaxis therapy, growth in home infusion programs • Growth Driver: Rising Prevalence Of Hemophilia Boosts Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kovaltry Market?

Kovaltry is a recombinant factor VIII (rFVIII) therapy that treats and prevents bleeding episodes in individuals with hemophilia A, a genetic disorder characterized by a deficiency in clotting factor VIII. It is manufactured using recombinant DNA technology and free from human- or animal-derived proteins, reducing the risk of infections. Administered intravenously, its dosage and frequency are tailored to the patient's weight, severity of factor VIII deficiency, and clinical requirements. The main types of formulations in kovaltry include injectable formulations (lyophilized powder) and ready-to-use solutions. Injectable formulation refers to a type of drug formulation designed to be administered through injection and intravenously to ensure rapid absorption and efficacy. The indications are categorized into treatment of hemophilia A, prophylaxis of hemophilia A, and management of bleeding episodes, and patient demographics include pediatric patients, adult patients, and geriatric patients. The distribution channels are direct sales; wholesalers and distributors; retail pharmacies; and online pharmacies for end users such as hospitals, hemophilia treatment centers, specialty clinics, and home healthcare providers.

What Is The Kovaltry Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of prophylaxis therapy, growth in home infusion programs, improved access in emerging markets, continued innovation in recombinant factors, stable demand for standard rfviii therapies. Major trends in the forecast period include shift toward recombinant factor viii therapies, expansion of prophylactic hemophilia a treatment, focus on infection free clotting factor products, growth of home based hemophilia management, personalized dosing regimens in bleeding disorders.

Global Kovaltry Market Segmentation

1) By Formulations: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions 2) By Indications: Treatment Of Hemophilia A, Prophylaxis Of Hemophilia A, Management Of Bleeding Episodes 3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End Users: Hospitals, Hemophilia Treatment Centers, Speciality Clinics, Home Healthcare Providers

What Are The Drivers Of The Kovaltry Market?

The rise in the prevalence of hemophilia is projected to propel the kovaltry market going forward. Hemophilia is a rare, inherited bleeding disorder where the blood does not clot properly due to the absence or deficiency of certain clotting factors. VIII and IX. The rise in the prevalence of hemophilia can be attributed to factors such as genetic mutations, increased awareness and diagnosis, and advancements in medical technologies that allow for better detection and reporting of the condition. Kovaltry helps reduce the prevalence of hemophilia by providing adequate and consistent clotting factor replacement, minimizing bleeding episodes. It supports long-term management, improving patients' quality of life and reducing complications. For instance, in June 2024, according to the Australian Bleeding Disorders Registry, an Australia-based government agency, the total number of patients with hereditary haemophilia in the country rose to 8,034 in 2024, up from 7,850 in 2022. Therefore, the rise in the prevalence of hemophilia drives the kovaltry industry. The rise in the aging population is anticipated to propel the kovaltry market going forward. The aging population is rising due to increased life expectancy, declining birth rates, and advancements in healthcare, leading to improved longevity. Kovaltry can be used in the aging population with hemophilia A to manage bleeding episodes and prevent complications, as older individuals may face increased risks of bleeding due to age-related changes in health and vascular conditions. For instance, in July 2023, according to Age UK, a UK-based registered charity for older people, in 2023, there are 11 million individuals aged over 65 in England. This number is expected to rise by 10% over the next five years and by 32% by 2043, translating to an increase of 1.1 million and 3.5 million people, respectively. Therefore, the rise in the aging population will drive the kovaltry industry. The increasing focus on personalized medicine is expected to propel the kovaltry market going forward. Personalized medicine is a medical approach that tailors treatment and preventive strategies to individual patients based on their genetic, environmental, and lifestyle factors. The focus on personalized medicine is rising due to advancements in genomics and biotechnology, growing awareness, regulatory support, and the shift toward value-based healthcare models. Increasing emphasis on personalized medicine is essential for kovaltry, as it emphasizes tailored treatment approaches that optimize dosing and therapeutic outcomes for hemophilia A patients, leveraging advancements in genetic profiling and individualized care to enhance effectiveness and patient satisfaction. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the increasing focus on personalized medicine drives the kovaltry industry.

Key Players In The Global Kovaltry Market

Major companies operating in the kovaltry market are Bayer HealthCare LLC

Regional Insights

North America was the largest region in the kovaltry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kovaltry Market?

The kovaltry market consists of sales of recombinant factor VIII therapy, infusion devices, patient support kits, prophylactic treatment products, and combination kits and ancillary products. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kovaltry Market Report 2026?

The kovaltry market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kovaltry industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.